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ABSTRACT 
Objective: In 2005, Tanzania changed its policy for uncomplicated malaria treatment from sulphadoxine–
pyrimethamine (SP) to artemisinin-based combination therapy (ACT), specifically artemether-lumefantrine 
(ALU).  SP remains the medicine of choice for intermittent preventive treatment in pregnancy (IPTp).  
There is a need to assess dispensers’ knowledge regarding the treatment of uncomplicated malaria and 
IPTp in Tanzania given appreciable self-purchasing to improve future care. Methods: Descriptive cross-
sectional design with structured questionnaires to capture quantitative data, with qualitative data captured 
using focus groups. The study was performed at 32 private pharmacies and 33 Accredited Drug 
Dispensing Outlets (ADDOs) in the Nyamagana and Sengerema Districts in Tanzania, with 20 dispensers 
included in the qualitative discussions.  Key findings: The knowledge level of dispensers in the private 
medicine outlets was variable. Most dispensers knew ALU was first line treatment in uncomplicated 
malaria; however variable knowledge about taking ALU with fatty meals. Generally poor knowledge about 
dosing intervals for SP in IPTp and variable knowledge regarding treatments in the first trimester. Overall, 
49% had good knowledge and 48% moderate knowledge of ACT in uncomplicated malaria. There was a 
significant relationship between dispenser type and knowledge of ACT but no statistical relationship 
between the level of knowledge on IPTp and the dispenser. Conclusion: Majority of dispensers in private 
medicines outlets have good knowledge on ACT policy in the treatment of uncomplicated malaria, 
however; few dispensers had good knowledge on IPTp, which may contribute to irrational dispensing of 
SP. This needs addressing given the extent of self-purchasing in Tanzania. 
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1. INTRODUCTION 
 
Malaria occurs most often in pregnant women and young children (1, 2). The greatest burden is in tropical 
regions (2-4), and in Africa malaria remains one of the most common diagnoses (5). For many years, 
malaria has been a leading cause of death in Sub-Sahara Africa especially among children (6, 7), 
although the number of deaths are decreasing (6, 8-10), helped by the availability of rapid diagnostic 
tests, prevention programmes and antimalarial medicines (10, 11). Malaria also has a significant impact 
on morbidity (7, 12). As a result, malaria is one of the leading public health concerns in infected countries, 
causing up to 660,000 deaths per year or higher (4, 10). Malaria is also a public health concern in 
Tanzania where in 2000, malaria accounted for over 43% of outpatient attendance, 42% of all hospital 
admissions and 32% of hospital deaths (6), with a similar situation in Uganda (13). The prevalence of 
confirmed malaria in children under five in Tanzania using a rapid diagnostic test (mRDT) in 2011 to 2012 
was 9% (14). The number of deaths have decreased in recent years in Tanzania,  down 68% between 
2005 and 2015 (8), with the number of reported cases down to six hundred and eight thousand in 2014 
from  1.28 million in 2010 (15). Never-the-less, malaria was the seventh highest cause of death in 
Tanzania in 2015 (8, 15). 
 
The impact of malaria can be far reaching. In pregnancy,  malaria can lead to birth complications, an 
increased risk of communicable and non-communicable diseases, and a high risk of both maternal and 
perinatal morbidity and mortality (2, 16, 17). Malaria in pregnancy contributes to an estimated 100,000 
neonatal deaths and 10,000 maternal deaths annually (17). In Nigeria, up to 11% of maternal deaths and 
30% of childhood deaths are due to malaria (2).  Malaria also results in considerable economic burden for 
households, including high co-payments for medicines in countries including Tanzania (4, 6, 9, 18-20) 
and reduced economic growth (4, 13, 21). In addition in children who survive, reduced educational 
attainment and intellectual development as a result of the time lost from schooling and the long-term 
sequelae (22). There is also loss of quality of life. The continued impact of malaria on morbidity and 
mortality in Tanzania ensures it is still a considerable public health problem necessitating appropriate 
care. 
 
In 2005, the Ministry of Health and Social Welfare, United Republic of Tanzania, changed the 
recommended treatment for uncomplicated malaria from sulphadoxine–pyrimethamine (SP) to 
artemisinin-based combination therapy (ACT) – specifically artemether-lumefantrine (ALU) (23). However, 
SP remains the medicine of choice for intermittent preventive treatment in pregnancy (IPTp) in Tanzania 
and across Africa (2, 10, 23, 24). ACT is also the recommended first line treatment in the second and 
third trimesters of pregnancy for uncomplicated malaria (2, 7, 25-27), with quinine still recommended for 
severe malaria across all trimesters as dihydroartemisinin/piperaquine (DPQ) as well as for second line 
treatment (2, 17, 28).  This is because of the suspected teratogenic effects of artemether during the first 
trimester. As a result, quinine is used in early pregnancy if needed unless the risks outweigh the benefits 
(2, 28). It is particularly important that medicines used in pregnancy are known to be safe (2, 26). IPTp 
has recently been shown to be highly cost effective for both prevention of maternal malaria and reduction 
in neonatal mortality in areas with moderate or high malaria transmission (29).  Despite the spread of SP 
resistance, IPTp continues to provide significant benefit, resulting in protection against both neonatal 
mortality as well as and low birth weights (30).  As a result, it continues to be recommended. 
 
The implementation of any new policy can be divided into technical and operational components as well 
as monitoring and evaluation. The technical components include regulatory changes, development and 
dissemination of essential medicines lists and standard treatment guidelines (STGs), as well as training 
and supervision of health care workers (31). To date, there has been greater efforts in training health 
service providers in the public sector in Tanzania on the use of ACT relative to the private sector, despite 
the vital role they both play in malaria treatment (32, 33).  This has also been seen in other countries (2, 
33). In Burundi, the highest knowledge regarding ACT therapy was in the charitable sector (90%), with 
lower levels in the private sector (55%) (34). Education of healthcare professionals is also important to 
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reduce over diagnosis of malaria, with implications for the development of resistance (35, 36). This is 
particularly important in sub-Sahara Africa where over 70% of patients with suspected malaria treat their 
illness with traditional remedies or medicines bought from pharmacies and other stores (35).  
 
The assumption that healthcare professionals will routinely follow STGs simply by just being available is 
optimistic, especially with their variable availability (37-40). This is a concern (40). with typically multiple 
approaches needed to enhance adherence to STGs(41-44). Multiple approaches resulted for instance in 
high adherence rates to recommended treatments in Sweden and other countries (45, 46). 
 
Currently, data evaluating health professional knowledge before or during the implementation of  the new 
ACT policy and IPTp in the private sector in Tanzania are scarce. Minzi et al (47) found a lack of 
involvement of pharmacy personnel working in private pharmacies in the development of guidelines, or 
training in their implementation, which contributed to poor knowledge and skills on how to correctly 
dispense medicines for malaria. Furthermore,  only 30% and 7% respectively of pharmacy personnel 
knew the correct dosing regimen for SP and ALU(47), with no one knowing the recommendation of taking 
ALU with a fatty meal for improved absorption (47). There are also concerns with the level of testing for 
malaria across facilities (48), with the availability of rapid tests, coupled with training, significantly reducing 
dispensing of antimalarials to patients without malaria (5).  
 
Consequently, we sought to address this gap by assessing the knowledge of dispensers in private 
medicine outlets in Tanzania regarding the treatment of uncomplicated malaria. We chose to investigate 
the private sector first given appreciable self-purchasing of antimicrobials in Tanzania including 
treatments for malaria in private facilities (6, 19, 20, 49), and there have been concerns with their 
knowledge of malaria treatment as well as other disease areas (6, 20, 47, 49, 50).   Self-purchasing can 
arise from long waiting times and shortages of medicines at health facilities, long distances to access 
health facilities as well as inability by some to pay for both health care and treatment (6).  
 
The findings of this study will be used to plan future interventions in Tanzania, if needed, to improve 
future management of these patients.  
 
2. MATERIAL AND METHODS                                                                                              
 
2.1 Study area and population 
This was a descriptive cross-sectional study including both qualitative and quantitative data. Qualitative 
data were captured based on focus group discussions among dispensers using guided questions. 
Quantitative data were captured using structured questionnaires.   
 
The study was conducted between October 2014 and May 2015 in the Mwanza region of Tanzania. This 
was conveniently selected because it is highly populated and is a holoendemic area for malaria 
transmission (49). The study population consisted of dispensers working at private pharmacies and 
Accredited Drug Dispensing Outlets (ADDOs) located in the Nyamagana and Sengerema Districts of the 
Mwanza region. Overall, this region has 7 districts. ADDOs currently have limited training compared to 
community pharmacists and can only dispense a limited number of medicines including those for 
uncomplicated malaria. 
 
2.2 Sample size, sampling technique  
For the quantitative study, we conducted interviews using structured questionnaires in 65 medicines 
outlets. This consisted of 33 ADDOs and 32 private pharmacies (out of a total of 47 Pharmacies and 50 
ADDOs in Nyamagana and Sengerema districts), with only one interviewee per outlet. We used the 
Daniel and Cross formula for calculating the sample size (51) and randomly sampled outlets (simple 
random sampling). The questionnaire was developed in English then translated in Swahili. It was piloted, 
with the final questionnaire refined to robustly assess the knowledge of dispensers on ACT policy and 
IPTp (Appendix 1). 
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Four focus group discussions were conducted among dispensers in the private medicine outlets with five 
participants in each, making a total of 20 dispensers.  Purposive sampling was employed for their 
selection. For qualitative data, the information obtained was transcribed and translated. The analysis was 
done manually using content analysis techniques (52). 
 
2.3 Data collection and analysis 
 
There were 22 questions to assess the knowledge of dispensers (Appendix 1). Table 1 shows the 
knowledge scale based on the number of correctly answered questions using the method of Kamuhabwa 
et al. (50). 
 
Table 1: Scale for measuring level of knowledge based on the number of correct answers 
 
 POOR MODERATE GOOD Total questions 
Treatment of 
uncomplicated 
malaria using ACT 
0-5 6-10 11-15 15 
IPTp 0-2 3-5 6-7 7 
 
The coded data were analyzed using Statistical Package for Social Sciences (SPSS - Version 20.0) 
computer analysis software. A P-value of less than 0.05 was considered as statistically significance. To 
protect dispensers’ privacy, no names were recorded and names of outlets were not mentioned in 
connection with the study’s results. Table 2 depicts the characteristics of the 55 respondents completing 
the questionnaire. 
 
Table 2: Social demographics of respondents in ADDOs (n=33) and Community Pharmacies (n=32) 
 
Demographics  Pharmacies ADDOs 
Frequency Percentage Frequency Percentage 
Sex     
 Male 15 46.9 11 33.3 
 Female 17 53.1 22 66.7 
Age (in years)     
 15-24 1 3.1 4 12.1 
 25-34 12 37.5 9 27.3 
 35-44 8 25 11 33.3 
 Above 45 11 34.4 9 27.3 
Profession     
 Pharmacist 5 15.6 0 0 
 Pharmaceutical 
technician               
15 46.9 0 0 
 Pharmaceutical 
assistants                 
4 12.5 0 0 
 5 weeks trained ADDO 
dispenser                              
6 18.8 26 78.8 
 Clinical officer                                 0 0 1 3 
 Nursing officer/nurse 
midwife         
1 3.1 1 3 
 Nurse Assistant                                0 0 3 9.1 
 Others 1 3.1 2 6.1 
Experience in dispensing     
 Less than 1 year 6 18.8 8 24.2 
  1 to 5 years 8 25 9 27.3 
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 6 to 10 years 9 28.1 9 27.3 
 11 years and above 9 28.1 7 21.2 
Attended training      
 Yes 4 12.5 1 3 
 No 28 87.5 32 97 
NB: *Others included Assistant clinical officer, Assistant medical officer and one year course medicine dispenser. 
 
The majority of dispensers in community pharmacies were pharmaceutical technicians, while in ADDOs 
none of the dispensers were pharmacists, with the majority undergoing five weeks training. 
 
For qualitative data, the information obtained was transcribed and translated. The analysis was done 
manually using content analysis techniques (52). 
 
2.4 Ethical Considerations  
Ethical clearance was obtained from the Ethical Review Committee of Muhimbili University of Health and 
Allied Sciences (MUHAS).  
 
3. RESULTS 
 
3.1 Results from Structured Questionnaire 
 
Table 3 shows the results of the dispensers’ knowledge survey.  Dispensers in ADDOs had consistently 
lower knowledge than dispensers in private pharmacies with the exception that respondents knew the 
number of days for dosing of ALU. However, only 40.2% of pharmacy dispensers and 18.2% of ADDOs 
dispensers correctly identified quinine tablets as recommended for uncomplicated malaria in first trimester 
of pregnancy.  Dispensers also showed poor knowledge of secondary treatment of uncomplicated malaria 
with only 34.4% of pharmacy and 9.1% of ADDOs dispensers mentioning DPQ tablets. Very few 
respondents were also able to mention the interval recommended for pregnant mother to take SP for 
IPTp. 
 
Table 3: Positive responses to questions assessing the knowledge of dispensers in the treatment of 
malaria using ACT and on IPTp 
 
 Private 
Pharmacies 
(n=32) 
ADDOs 
(n=33) 
Total 
(n=65) 
Q: Mention the first line medicine for treatment of 
uncomplicated malaria 
A: ALU is the first line medicine for the treatment of 
uncomplicated malaria 
100% 90.9% 95.4% 
Q: ALU is not recommended to which group of                                                                         
individuals? 
A: ALU is not recommended in pregnancy during first trimester 
65.6% 42.4% 54.1% 
Q: Which medicine is recommended for treatment for 
uncomplicated malaria in first trimester of pregnancy?  
A: Quinine tablets are the medicine recommended in first 
trimester where benefits outweigh the risks                                                                     
40.6% 
 
18.2% 29.4% 
 
Q: What is the reason for ALU to be taken with fat meals? 
A: ALU should be taken with fat meals so as to increase its 
absorption                                     
56.3% 24.2% 40.2% 
Q: The dosage of ALU has to be taken for how many days? 
A: A dosage regimen of ALU is taken for 3 days 
100% 100% 100% 
Q: Mention second line medicine for treatment of 
uncomplicated malaria 
34.4% 9.1% 22% 
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A: Second line anti-malarial treatment is DPQ tablets 
Q: What is the interval recommended for the pregnant mother 
to take SP for IPTp 
A: Interval recommended for the pregnant mother to take SP 
for IPTp it is every clinic visit from second trimester, i.e. 
monthly 
6.3% 6.1% 6.2% 
Q: What will be the effect of administering SP for the use other 
than IPTp e.g. for treatment of uncomplicated malaria 
A: When SP is used for treatment of malaria rather than IPTp - 
it may result in SP resistance for IPTp 
53.1% 24.2% 38.6% 
NB: Q: question; A: answer 
 
Encouragingly, most dispensers in ADDOs (72.7%) and 50% of dispensers in private pharmacies 
mentioned SP respectively, and 40.6% of dispensers mentioned quinine, as the treatment of 
uncomplicated malaria in the first trimester of pregnancy. However only 18.2% of ADDOs mentioned 
quinine. The remainder, i.e. 9.4% of community pharmacies and 9.1% ADDOs, included respondents who 
did not know the treatment; alternatively, suggested DPQ and sulphamethoxypyrazine / pyrimethamine 
(SPP). 
 
Overall, 49.2% of dispensers had good knowledge on the treatment of malaria using ACT based on Table 
1, 47.7% moderate knowledge and 3.1% poor knowledge. There was worse knowledge regarding IPTp 
with only 15.2 % of dispensers in community pharmacies having good knowledge (0% in ADDOs), 66.7% 
having moderate knowledge (65.6% in ADDOs) and 18.2% poor knowledge (34.4% for ADDOs). 
 
Tables 4 and 5 summarizes the knowledge levels of dispensers by type and if the dispenser attended any 
training session on malaria treatment. Table 4 evaluates dispenser’s level of knowledge on ACT by the 
type of dispenser and their training whilst Table 5 assess dispensers’ level of knowledge on IPTp, again 
by the type of dispenser and their training (n=65). There was a statistical significant relationship between 
the type of dispenser and his/her level of knowledge on ACT (P=0.007). However, there was no statistical 
significant relationship between type of dispenser and his/her knowledge on IPTp (P=0.075). 
 
Table 4: Dispenser’s level of knowledge on ACT by type of dispenser and attending training (n=65) 
 
Demographics                                         Level of Knowledge Total P value 
 Poor Moderate Good   
Profession/ Type of dispenser      
 Pharmacist 0(0%) 2(40%) 3(60%) 5 0.007 
Pharmaceutical 
technician 
0(0%) 2(13.3%) 13(86.7%) 15 
Pharmaceutical 
assistant 
0(0%) 2(40%) 3(60%) 5 
ADDO dispenser 1(3.1%) 20(62.5%) 11(34.4%) 32 
Clinical officer 0(0%) 0(0%) 1(100%) 1 
Nursing 
officer/nurse 
midwife 
0(0%) 2(100%) 0(0%) 2 
Nurse assistant 1(50%) 1(50%) 0(0%) 2 
Others 0(0%) 2(66.7%) 1(33.3%) 3 
Attending training      
 Yes 0(0%) 0(0%) 5(100%) 5 0.066 
No 2(3.3%) 31(51.7%) 27(45%) 60 
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Table 5: Dispenser’s level of knowledge on IPTp by profession of the dispenser and attending training 
(n=65) 
 
Demographics                                         Level of Knowledge Total P value 
 Poor Moderate Good   
Profession      
 Pharmacist 1(20%) 3(60%) 1(20%) 5 0.075 
Pharmaceutical 
technician 
2(13.3%) 9(60%) 4(26.7%) 15 
Pharmaceutical 
assistant 
1(20%) 4(80%) 0(0%) 5 
ADDO dispenser 10(31.2%) 22(68.8%) 0(0%) 32 
Clinical officer 0(0%) 1(100%) 0(0%) 1 
Nursing officer/nurse 
midwife 
1(50%) 1(50%) 0(0%) 2 
Nurse assistant 2(100%) 0(0%) 0(0%) 2 
Others 0(0%) 3(100%) 0(0%) 3 
Attended training      
 Yes 0(0%) 5(100%) 0(0%) 5 0.416 
No 17(28.3%) 38(63.4%) 5(8.3%) 60 
 
3.2 Results from focus group discussion 
 
None of the participants in the focus discussion groups had attended training or a seminar on the 
treatment of uncomplicated malaria.  All participants mentioned ALU as the first line medicine.  
 
When asked why SP was prohibited for use as treatment, only one respondent knew the reason. One of 
them said: 
 
 “The government has forgotten private sector, there are new changes in malaria treatment but we didn’t 
receive any training, we depend on reading drug leaflets. So the Ministry of Health should conduct 
trainings for the private sector.” (Private Pharmacy Participant) 
 
Dispensers typically didn’t know that DPQ is the recommended second line medicine for treatment of 
uncomplicated malaria. SP was mentioned by all for IPTp.  
  
One of the participants said “From what I know, Quinine tablets is the second line anti malaria and in case 
of treatment failure Quinine injections should be used” (ADDO Participant) 
 
Most participants when asked why SP should not be used for treatment of uncomplicated malaria failed to 
mention it is because of a change in the treatment policy from SP to ALU due to potential treatment 
failure of SP, although they were aware of potential allergic reactions. Consequently, they continued 
dispensing SP for malaria treatment, which can lead to SP resistance in IPTp.  
 
 One of them said: 
“SP is reserved for pregnant mothers because it kills malaria parasite available in the placenta.” (ADDO 
Participant) and another one said “SP is not supposed to be used for treatment of malaria because of 
allergic reaction to patients, but it doesn’t have allergic reaction to pregnant mothers due to their 
antibodies.” (Private Pharmacy Participant) 
 
Another participant said “Some years ago SP was used for treatment of Uncomplicated Malaria but 
recently I heard some news through mass media that new medicine to be used should be ALU since it is 
more effective than SP” (ADDO Participant)  
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4. DISCUSSION 
 
The use of artemisinin-based combinations is recommended for the treatment of uncomplicated malaria 
in all age groups, except during the first trimester of pregnancy (2, 7, 25, 27). Dispensers’ knowledge of 
malaria treatment recommendations is vital to enhance appropriate prescribing and dispensing of ACT, 
even more so given the extent of self-treatment for malaria in Tanzania (6, 19, 20).  
 
There were encouraging signs in the knowledge of dispensers regarding the management of patients with 
malaria, but also areas of concern that need to be address. This compares favourably with other 
countries where there were serious concerns with the level of knowledge among certain providers 
including issues of treatment length (2, 16, 33, 53). 
 
Encouragingly, more than 95% of dispensers (Table 3) knew that ALU is first line treatment for 
uncomplicated malaria with 100% knowing the dosage regimen. This is welcomed with concerns with self-
purchasing ACT in other African countries due to costs (7, 25). However, a lower number of dispensers 
knew why ALU should be taken with fatty meals, i.e. to increase its absorption, although an appreciable 
improvement on previous studies (47). This is a concern as dispensers who do not know the importance 
of taking ALU with fatty foods may provide inadequate instructions to their clients, which may lead to 
underperformance of ALU. This is because taking ALU without consuming milk or fatty food has a 
significant impact on its bioavailability (54). In addition, only a limited number of dispensers knew that 
quinine is the recommended medicine for treatment of uncomplicated malaria in first trimester pregnancy 
(Table 3). However, a greater number knew that ALU is not recommended in the first trimester. Rates 
lower than 100% though mean it is more likely that pregnant mothers in first trimester who seek self-
treatment will get ALU, which could potentially endanger their fetus. This needs to be addressed. 
 
Encouragingly, most dispensers mentioned SP as the drug of choice for malaria in pregnancy, although 
knowledge rates could be appreciably improved. Nearly all dispensers also had moderate or good 
knowledge regarding the treatment of uncomplicated malaria. This compares favourably to the greater 
use of non-recommended treatments for malaria in pregnant women in private versus public facilities in 
Nigeria (2). However, a third of ADDO personnel had poor knowledge of the management of IPTp 
although appreciably better knowledge in private pharmacies. This might be due to the fact that more 
than 75% of dispensers in ADDOs had only five weeks training and none was either pharmacist or 
pharmaceutical technician (Table 2), whilst the majority of pharmacists had more than six years’ 
experience in dispensing.  
 
Disappointingly, only 22% of dispensers knew that DPQ was the second line (Table 3); although again 
higher among private pharmacies than ADDOs. Overall, the use of second line treatments does not 
appear well known among dispensers in private medicine outlets. Other concerns include the fact that 
most dispensers had inadequate knowledge regarding IPTp (Table 3). This is an issue given the cost-
effectiveness of treatment for IPTp (24). Very few dispensers also knew the dosing interval recommended 
for pregnant mothers to take SP for IPTp. In addition, only 39% of dispensers knew that the using SP for 
uncomplicated malaria, instead of reserving it for IPTp, may lead to SP resistant (Table 3), which in turn 
will compromise its future effectiveness. As seen in the focus group discussions, most participants also 
failed to mention the policy change from SP to ALU. This means most dispensers in private outlets may 
irrationally dispense SP for malaria treatment because they do not know its impact.  This also needs to be 
addressed. 
 
Overall, there was a statistical relationship (p value <0.05) in the level of knowledge regarding ACT for the 
treatment of uncomplicated malaria with the professional level of dispensers (Table 4). Disappointingly, 
only a third of ADDO dispensers had good knowledge (Table 4) versus higher levels among private 
pharmacies. This is despite the availability of a training manual for ADDO dispensers with a special 
section explaining in detail about malaria treatment. However, most of ADDO dispensers were trained 
before the change in the  malaria treatment guideline and there are generally concerns with their 
knowledge of even basic pharmacology (49). This lack of training and their limited qualifications may have 
contributed to their moderate to poor knowledge (Tables 4 and 5).   
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Based on our findings, there does appear to be the need for more training for dispensers in the private 
medicine outlets in Tanzania especially ADDO dispensers. This need is further endorsed by the fact that 
all participants in the focus group discussion said that they have never been involved in training and most 
didn’t know about the changes in the malaria treatment guidelines. This needs to be urgently addressed 
given the priority status for malaria in Tanzania coupled with the fact that malaria training has worked well 
in other countries (25). 
 
The major limitation of this study is that the findings were restricted to only dispensers and private 
facilities in one region of Tanzania. However, we will be undertaking additional research in other regions 
as well as public pharmacies to further assess the level of knowledge in this priority area in Tanzania. In 
the meantime, we believe based on the nature of the study design that our findings are robust and give 
guidance to the authorities in Tanzania on ways to enhance the management of malaria in pharmacies 
and ADDOs. 
 
5. CONCLUSION                                                                                                                       
 
Encouragingly, the majority of dispensers in private outlets in Tanzania appeared to have moderate to 
good knowledge regarding the ACT policy in the treatment of uncomplicated malaria. However, there are 
important gaps including general knowledge levels among ADDO dispensers versus private pharmacists. 
These include low awareness that ALU should be taken with fatty foods, that quinine is the recommended 
treatment in the first trimester and that DPQ is generally second line treatment. Knowledge regarding the 
management of IPTp can also be improved especially among ADDO personnel.  
 
As a result, the Ministry of Health and other stakeholders should urgently conduct training courses and 
seminars for private outlet dispensers in Tanzania to address key knowledge gaps in this high priority 
disease area. Both the government and donors should also engage the private sector in the ACT policy 
implementation process in the future to improve the management of these patients to fully utilize this 
important sector. We will be following this up, including researching the impact of future educational 
interventions, to ensure the optimal management of patients with malaria in Tanzania given its public 
health priority.  
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